Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improving Inhaler Treatment and Small Airways Assessment in COPD
NCT01721291Phase 4Completed
- Sponsor
- Imperial College London
- Start
- Oct 2012
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of salbutamol in chronic obstructive pulmonary disease (COPD) and asthma (4 arms), sponsored by Imperial College London. Primary endpoints: Penetration Index at 5 minutes, Conductive ventilation heterogeneity (Scond) from Multiple Breath Nitrogen Washout (MBNW) at 30 minutes and 1 more. Started Oct 2012; status: completed.
02
Drugs
salbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)asthma
Beyond the preview
Go deeper on NCT01721291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721291.